Today, a brief rundown of news involving Evotec, Bluebird bio and the company formerly known as BeiGene, as well as updates from Leerink Partners and Abeona Therapeutics that you may have missed.

今天，简要介绍了Evotec、Bluebird bio和之前称为BeiGene的公司的新闻，以及Leerink Partners和Abeona Therapeutics的最新消息，您可能错过了这些消息。

Halozyme Therapeutics has made an unsolicited bid to buy drug discovery specialist Evotec for 11 euros per share in cash, an offer worth some 2 billion euros in total. In a press release, Halozyme said the combined company could offer increased scale and become a “highly attractive strategic partner” to the drug industry.

Halozyme Therapeutics主动提出以每股11欧元的现金收购药物发现专家Evotec，总价值约20亿欧元。Halozyme在新闻稿中表示，合并后的公司可以扩大规模，成为制药行业“极具吸引力的战略合作伙伴”。

Evotec, in its own statement, said it would “carefully analyze this expression of interest.” — Ned Pagliarulo.

Evotec在自己的声明中表示，它将“仔细分析这种兴趣表达。”-内德·帕利亚鲁洛。

Bluebird bio has recorded its first revenue from sales of Lyfgenia, the company’s gene therapy for sickle cell disease that won U.S. approval late last year. The process to prepare and receive Lyfgenia is lengthy, so only recently did the first patient actually get an infusion, at which point Bluebird books revenue for the $3.1 million therapy. Another 16 patients have started the process to receive treatment.

蓝鸟生物（Bluebird bio）首次从销售Lyfgenia中获得收入，Lyfgenia是该公司治疗镰状细胞病的基因疗法，去年年底获得美国批准。准备和接受Lyfgenia的过程很长，因此直到最近第一位患者才真正接受输液，此时蓝鸟为310万美元的治疗创造了收入。另外16名患者已经开始接受治疗。

The company is counting on climbing demand for Lyfgenia and its two other gene therapies, Zynteglo and Skysona, as it works to break even. Currently, it has enough cash to fund operations into the first quarter. — Ned Pagliarulo.

该公司正指望对Lyfgenia及其另外两种基因疗法Zynteglo和Skysona的需求不断攀升，以实现收支平衡。。-内德·帕利亚鲁洛。

Cancer drugmaker BeiGene will now operate under the name BeOne Medicines, a change that it says reflects its commitment to oncology research. The name also distances the company from its roots in China, a connection that may be less helpful as lawmakers in the U.S. increasingly view such ties as a national security risk.

癌症药物制造商BeiGene现在将以BeOne Medicines的名称运营，该公司表示这一变化反映了其对肿瘤学研究的承诺。这个名字也使该公司远离了其在中国的根基，这种联系可能没有什么帮助，因为美国立法者越来越多地将这种联系视为国家安全风险。

BeOne, which trades on the Hong Kong and Shanghai stock exchanges as well as the Nasdaq, is headquartered in California and in Switzerland. — Ned Pagliarulo.

BeOne总部位于加利福尼亚州和瑞士，在香港和上海证券交易所以及纳斯达克进行交易。-内德·帕利亚鲁洛。

Adaptimmune will lay off a third of its workforce in a bid to save about $300 million and break even financially in 2027, the company said Wednesday. Adaptimmune in August won U.S. clearance for its first product, a cell therapy called Tecelra for a type of soft tissue cancer. Going forward, the company will focus resources on that launch and another program in development for similar cancers, while partnering off two unrelated projects in preclinical testing.

Adaptimmune周三表示，该公司将裁员三分之一，以节省约3亿美元，并在2027年实现财务收支平衡。Adaptimmune于8月份获得了其首个产品的美国许可，该产品是一种称为Tecelra的细胞疗法，用于治疗一种软组织癌。展望未来，该公司将把资源集中在该项目的启动和针对类似癌症的另一个正在开发的项目上，同时在临床前测试中合作完成两个不相关的项目。

It’s also shutting down a Phase 2 study in ovarian tumors. — Ben Fidler.

它也停止了卵巢肿瘤的2期研究。-本·菲德勒。

Leerink Partners has named two senior managing directors, Grant Curry and Jason Truman, to join its biopharma M&A team. Truman previously worked in a similar role at Guggenheim Securities, while Curry was a managing director at Gordon Dyal & Co. Leerink, which reemerged via a management buy-out after the collapse of SVB Financial Group, hopes to grow its M&A business.

Leerink Partners已任命两名高级董事总经理Grant Curry和Jason Truman加入其生物制药并购团队。杜鲁门之前曾在古根海姆证券（Guggenheim Securities）担任过类似的职位，而库里（Curry）是戈登·戴尔（Gordon Dyal＆Co.）的董事总经理。莱林克（Leerink）在SVB金融集团（SVB Financial Group）倒闭后通过管理层收购重新合并，希望扩大其并购业务。

Outside of the big banks, Centerview Partners, Lazard and PJT Partners currently win the most deal business from drugmakers, according to BioPharma Dive data. — Ned Pagliarulo.

根据BioPharma Dive的数据，除大银行外，Centerview Partners、Lazard和PJT Partners目前从制药商那里赢得了最多的交易业务。-内德·帕利亚鲁洛。

By the end of next April, Abeona Therapeutics should know whether the Food and Drug Administration will approve its gene therapy pz-cel for a rare wound healing condition known as recessive dystrophic epidermolysis bullosa. The agency rejected pz-cel this past April, asking Abeona for more information on how it’s produced. The company then resubmitted its application with new information and, on Thursday, secured a target decision date of April 29, 2025 from the agency. — Ned Pagliarulo.

到明年4月底，Abeona Therapeutics应该知道美国食品和药物管理局是否会批准其基因疗法pz-cel治疗一种罕见的伤口愈合疾病，即隐性营养不良性大疱性表皮松解症。今年4月，该机构拒绝了pz cel，要求阿博纳提供有关其生产方式的更多信息。该公司随后以新信息重新提交了申请，并于周四从该机构获得了2025年4月29日的目标决定日期。-内德·帕利亚鲁洛。